Davion Healthcare tumbles 11%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Davion Healthcare (DAVI.US) tumbled nearly 11% during regular trading to $1.50.

The stock is down 87.76% over the past ten sessions and down 87.76% from its first-day open. It sits 87.80% below its 52-week high of US$12.30. The intraday swing reached 10.71%.

The Nasdaq Composite is down 2.15% over the past five sessions and up 10.18% year to date.

The company completed the acquisition of WoundSkan and Spektra Lateral Flow Test intellectual property from Humaskan shareholders for $25 million, paid in cash and newly issued shares. The stock had fallen more than 18% in premarket trading following the announcement.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.